ADC Therapeutics SA Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ADC Therapeutics SA (ADCT) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$42.23 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-13
- ADC Therapeutics SA cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$30.32M.
- ADC Therapeutics SA cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$56.33M.
- ADC Therapeutics SA cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$44.27M.
- ADC Therapeutics SA cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$15.98M.
- ADC Therapeutics SA cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $10.17M.
- ADC Therapeutics SA cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$27.65M.
- ADC Therapeutics SA cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$48.03M.
- ADC Therapeutics SA cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$139.90M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$42.23M 10-Q · filed 2026-08-13 | |||
| 2026-03-31 | -$30.32M 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $10.17M 10-K · filed 2026-03-10 | |||
| 2025-09-30 | -$16.46M 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $13.37M 10-Q · filed 2026-08-13 | |||
| 2025-03-31 | -$56.33M 10-Q · filed 2026-05-04 | |||
| 2024-12-31 | -$27.65M 10-K · filed 2026-03-10 | |||
| 2024-09-30 | -$4.59M 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $21.55M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | -$44.27M 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | -$48.03M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | -$16.07M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | $20.92M 10-Q · filed 2024-08-06 | |||
| 2023-03-31 | -$15.98M 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | -$139.90M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |